Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Anika Therapeutics, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Anika Therapeutics, Inc.

Regulatory records
5
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 5 FDA records to the applicant name Anika Therapeutics, Inc.. The collection includes 2 510(k) clearances. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Oct 15, 2025 to Sep 17, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LZP appears in 2 of the 5 linked filings. The collection spans 4 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P000046, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 32 Wiggins Ave., Beford, MA, 01730, US. Recorded on K261869, decision dated Sep 17, 2026.

Changes described in PMA records

P000046/S032: Ophthalmic Viscosurgical Device Family

FDA’s recorded scope: the replacement of reusable components with single-use, presterilized components for use during transfer steps of the formulation and fill process during manufacturing of the subject sodium hyaluronate devices

Aug 28, 2026 · 30-Day Notice

P030019/S028: Orthovisc Injectable Intra-Articular Devices

FDA’s recorded scope: the replacement of reusable components with single-use, presterilized components for use during transfer steps of the formulation and fill process during manufacturing of the subject sodium hyaluronate devices

Aug 28, 2026 · 30-Day Notice

P000046/S031: Ophthalin; Nuvisc; Anikavisc

FDA’s recorded scope: a replacement adhesive laminate film for the sealed pouch used as a sterile barrier system for the subject ophthalmic viscosurgical device

Oct 15, 2025 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Anika Therapeutics, Inc.510(k) clearanceSep 17, 2026FDA
Anika Therapeutics, Inc.510(k) clearanceSep 2, 2026FDA
Anika Therapeutics, Inc.PMA supplementAug 28, 2026FDA
Anika Therapeutics, Inc.PMA supplementAug 28, 2026FDA
Anika Therapeutics, Inc.PMA supplementOct 15, 2025FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.